Table 3.
Biomarker Selected Studies Currently Recruiting
| NCT | Phase | Biomarker | Therapeutics | MOA |
|---|---|---|---|---|
| NCT03213626 | II | EGFR and c-MET overexpresssion by IHC | cabozantinib and erlotinib | c-Met/VEGFR2 |
| NCT01489865 | I/II | BRCA or BRCAness (BRCA1, BRCA2, PALBB2, or one of the FANC genes, personal history of BRCA related malignancy, multiplex family) | ABT888 and mFOLFOX6 | PARPi |
| NCT01506973 | I/II | JNK1 | Hydroxychloroquine + gemcitabine/nab-paclitaxel | autophagy inhibitor |
| NCT01585805 | II | Germline BRCA 1 or 2 or PALB2 | Gemcitabin/Cisplatin +/− veliparib, veliparib alone | PARPi |
| NCT02184195 | III | Germline BRCA 1/2 | Olaparib after 16 weeks of platinum without progression | PARPi |
| NCT02350673 | I | CEA | Cergutuzumab and Atezolizumab | CEA targeted IL-2 variant + PDL1 inhibitor |
| NCT02395016 | III | KRAS WT | nimotuzumab | EGFR antagonist |
| NCT02672917 | I | CA19-9 | MVT-5873 | anti-CA19-9 monoclonal antibody |
| NCT02715804 | III | Hyaluronic Acid | Gemcitabine/nab-paclitaxel +/− PEGPH20 | Pegylated hyaluronidase |
| NCT02744287 | I | PSCA | BPX-601 | Prostate stem cell antigen directed CART |
| NCT03023722 | II | Mesothelin | Anetumab ravtansine | mesothelin monoclonal antibody conjugated to DM4 |
| NCT03040986 | II | KRAS G12R mutation | Selumetinib | MEK inhibitor |
| NCT03118349 | I | CA19-9 | MVT-1075 | 177Lu labeled anti-CA19-9 Mab |
| NCT03140670 | II | Deleterious BRCA1/2 or PALB2 mutation | Rucaparib after 16 weeks of platinum without progression | PARPi |
| NCT03323944 | I | Mesothelin | huCART-meso cells | Mesothelin directed CART |
CART: chimeric antigen receptor T-cell